Columvi Roche Products Pty Ltd
Product name
Columvi
Sponsor
Accepted date
Sep-2024
Active ingredients
glofitamab
Proposed indication
For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.
Application type
C (new indication)
Publication date
Sep-2024